Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057

SHIRE

(SHP)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Elliott Capital Advisors, L.P: Form 8.3 - Shire PLC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2018 | 10:25am EDT

            FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)
           
1.         KEY INFORMATION

(a) Identity of the person whose positions/dealings are being disclosed:Elliott Capital Advisors, L.P. (for itself and related general partners and investment managers)
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
  The naming of nominee or vehicle companies is insufficient
Elliott International, L.P.
Liverpool Limited Partnership
Elliott Associates, L.P

 
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:
  Use a separate form for each offeror/offeree
Shire Plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: 
(e) Date position held/dealing undertaken:6thDecember 2018
(f)  Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?Yes, Takeda Pharmaceutical Company Limited

2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: Ordinary shares: JE00B2QKY057

 
 
 

 
InterestsShort positions
Number%Number%
(1) Relevant securities owned and/or controlled:100.0000%  
(2) Derivatives (other than options):7,789,7020.8505%  
(3) Options and agreements to purchase/sell:    
 

  TOTAL:
7,789,7120.8505%  


Class of relevant security:
Depositary Receipts over Ordinary Shares (“DRs”) : US82481R1068
 

(Note: One DR = 3 Ordinary Share)
 

 
InterestsShort positions
Number%Number%
(1) Relevant securities owned and/or controlled:5370.0000%  
(2) Derivatives (other than options):467,4500.1531

 
%

  
(3) Options and agreements to purchase/sell:    
 

TOTAL:
 

467,987
 

0.1533


%
  

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)        Rights to subscribe for new securities (including directors’ and other executive options)

Class of relevant security in relation to which subscription right exists: 
Details, including nature of the rights concerned and relevant percentages: 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

(a)        Purchases and sales

Class of relevant securityPurchase/sale

 
Number of securitiesPrice per unit
    

(b)        Derivatives transactions (other than options)

Class of relevant securityProduct description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securitiesPrice per unit
ORDEquity swapIncreasing a long position325,000USD 58.8066
     

(c)        Options transactions in respect of existing securities

(i)         Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType
e.g. American, European etc.
Expiry dateOption money paid/ received per unit
        

(ii)        Exercising

Class of relevant securityProduct description
e.g. call option
Number of securitiesExercise price per unit
    

 

(d)        Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing
e.g. subscription, conversion
DetailsPrice per unit (if applicable)
  

 
  

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

4.         OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
If there are no such agreements, arrangements or understandings, state “none”
 

NONE

 

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i)  the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
 

NONE

 

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?NO

                       

Date of disclosure:7thDecember 2018
Contact name:Michael Cross
Telephone number:0203 009 1305

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.  The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

© OMX, source OMX

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHIRE
05/16TAKEDA PHARMACEUTICAL : Bracing for 383-B.-Yen Net Loss for FY 2019
AQ
05/14TAKEDA PHARMACEUTICAL : expects net loss in FY 2019 due to Shire buyout cost
AQ
04/26TAKEDA PHARMACEUTICAL : Revised Forecast of Consolidated Financials for FY2018
AQ
02/18TAKEDA PHARMACEUTICAL : Notice Regarding Issue of Hybrid Bonds to replace Senior..
AQ
02/15SHIRE : Annual results
CO
02/08Kamada Announces Additional Interim Results from Phase 2 Proof of Concept Cli..
AQ
01/18Alder BioPharmaceuticals Appoints Paul Streck, M.D. Chief Medical Officer
AQ
01/18Alder BioPharmaceuticals Appoints Paul Streck, M.D. Chief Medical Officer
AQ
01/14TAKEDA PHARMACEUTICAL : Shire and SAIIDAC announce planned delisting of notes fr..
AQ
01/11SHIRE PLC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
Financials ($)
Chart SHIRE
Duration : Period :
Shire Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
Howard Mayer Chief Medical Officer
Matthew Walker Head-Technical Operations
Andreas Eugen Busch Chief Scientific Officer
Amitabh Singh Director
Susan O’Reilly Secretary & Director
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE0.00%0
JOHNSON & JOHNSON7.03%367 513
PFIZER-4.54%231 237
ROCHE HOLDING LTD.9.70%226 519
NOVARTIS12.54%207 417
MERCK AND COMPANY4.04%203 088